Static Magnets for Period Pain: What the Research Actually Show

For them, static magnetic field therapy raises an interesting question.

Is there actually clinical evidence that a permanent magnet placed over the pelvis or painful abdominal area can reduce menstrual pain?

Surprisingly, the answer is yes. But with important qualifications.

Two randomized, blinded pilot studies have specifically investigated static magnets for dysmenorrhea, and both reported statistically significant benefits compared with control devices. A separate randomized trial in women with chronic pelvic pain also produced encouraging results after longer exposure.

These studies are small. They do not establish static magnets as a universally effective treatment for menstrual pain. But they provide substantially more direct clinical evidence than many people would probably expect.

Medication Works-but Some Women Want Another Option

Any discussion of non-drug pain management needs to avoid creating a false choice between “natural” treatment and conventional medicine.

NSAIDs are effective for many women with dysmenorrhea and, when used occasionally and according to directions, over-the-counter pain relievers are considered safe and effective for most appropriate users. Hormonal contraception can also make periods lighter and less painful.

With NSAIDs such as ibuprofen and naproxen, serious adverse effects are uncommon with appropriate short-term use, but can include gastrointestinal ulceration or bleeding and kidney injury, particularly in susceptible people or when doses are excessive or prolonged.

Paracetamol-known as acetaminophen in North America-is another common pain reliever. It is generally safe at the recommended dose, but excessive dosing can cause severe liver injury, liver failure and death.

Hormonal treatments have a different risk profile. For example, the combined contraceptive pill can improve period pain considerably, but combined hormonal contraception carries a small risk of blood clots. The NHS estimates this at up to around 1 in 1,000 users, with serious complications potentially including pulmonary embolism, heart attack or stroke. These risks are one reason clinicians screen for individual risk factors before prescribing it.

None of this is an argument against medication.

It is simply part of an informed comparison. A woman who gets reliable relief from ibuprofen or hormonal treatment without troublesome effects may have little reason to change. Another woman may reasonably decide that she would like to investigate a non-pharmaceutical approach either instead of medication where medically appropriate, or as part of a broader pain-management strategy.

That is where the static-magnet research becomes relevant.

Study 1: Eccles – Static Magnet Therapy for Dysmenorrhea

In 2005, physician and researcher Nyjon Eccles published a randomized, double-blinded, placebo-controlled pilot study specifically investigating static magnetic therapy for primary dysmenorrhea.

Sixty-five women with regular dysmenorrhea entered the study and 35 completed it. Participants were randomly assigned either an active magnetic device rated at 2700 gauss or an apparently identical low-strength magnetic control rated at 140 gauss.

What magnet did Eccles use?

The active device was a specially designed neodymium static-magnet system. It used a directional arrangement incorporating permanent magnets and a steel plate to concentrate the field toward the body.

In terms of the Q Magnets product family, the closest conceptual comparison is the BF28-3N Bio-North bipolar format. Their dimensions, construction and measured field characteristics differ. The current BF28-3N is itself a neodymium bipolar device with a flux plate.

Where was the magnet placed?

The device was positioned over the pelvic area, anterior to the pubis.

This is interesting when compared with the current Q Magnets Primary Placement, which begins with a magnet in the midline pelvic region immediately above the pubic bone.

The anatomical logic is remarkably similar.

How long was it worn?

Eccles used a relatively large exposure dose.

Women were instructed to begin wearing the device approximately two days before the expected beginning of menstruation and to continue wearing it, apart from bathing, until the menstrual period had finished.

This was therefore not a brief laboratory exposure. It was effectively a pre-emptive and continuing treatment across the symptomatic portion of the menstrual cycle.

What happened?

The active-magnet group experienced significantly greater pain reduction than the control group, with p < 0.02.

The study reported an average reduction in pain of approximately 53% in the active-magnet group compared with about 15% in the low-strength control group. Approximately 70% of women using the active magnet achieved at least a 50% reduction in pain.

That is a clinically interesting result.

There are limitations. Only 35 of 65 enrolled women completed the trial, it assessed a single menstrual cycle, and the placebo was actually a weak magnet rather than a completely non-magnetic sham. The study was also associated with the manufacturer supplying the device.

While those qualifications matter, they do not erase the randomized comparison or the significant difference between groups.

Study 2: Mayrovitz – A Very Different Test of the Same Basic Idea

Sixteen years later, Harvey Mayrovitz and colleagues approached menstrual pain quite differently.

Their 2021 randomized, blinded pilot trial included 36 women aged 18–35 who regularly experienced menstrual pain of at least 6 out of 10. Women with secondary dysmenorrhea, including conditions such as endometriosis and fibroids, were excluded, as were women who had taken pain medication on the study day.

Nineteen received the active magnet and 17 received a visually similar sham.

What magnet did Mayrovitz use?

It was a concentric alternating-pole neodymium magnet, consisting of a central magnetic element surrounded by an oppositely arranged outer ring and backed by a ferromagnetic plate. Its reported surface field reached approximately 0.4 Tesla, or 4,000 gauss.

The outer diameter was approximately 25.4 mm.

This is very close to the CF28-3 concentric magnet, which is a 28 mm × 3 mm neodymium device using an alternating concentric field arrangement and flux plate.

Where did they put it?

This is perhaps the most interesting element of the study.

Instead of prescribing one standard anatomical point for everybody, the participant palpated her abdomen and identified the location where her menstrual pain was greatest.

The magnet or sham was then attached directly over that point.

That is a very simple form of individualised placement.

And for how long?

Only 40 minutes.

Participants were allowed to go about normal daily activities during that period, although they did not exercise or take pain-relieving medication.

Despite this very short exposure, the result was significant.

Average pain fell from approximately 7.16 to 4.16 in the active-magnet group, compared with approximately 6.94 to 5.53 in the sham group.

The investigators defined a reduction of at least 35% as meaningful. On that criterion:

The proportion achieving meaningful relief differed significantly between groups (p = 0.013), and post-treatment pain scores were also significantly lower with the active magnet (p = 0.027).

Once again, this was a small pilot trial. It measured only one 40-minute treatment session and did not determine how long the benefit lasted after the magnet was removed.

But the result raises an obvious question:

If 40 minutes of accurately targeted exposure produced a measurable effect, what might happen with an appropriately designed longer-duration study?

The authors themselves recommended investigating longer treatment periods.

Study 3: Brown – Chronic Pelvic Pain and the Importance of Trigger Points

A third study should not be described as a dysmenorrhea trial, because it was not.

In 2002, Brown and colleagues investigated women with chronic pelvic pain using a randomized, double-blind, placebo-controlled design. Thirty-two participants completed two weeks of treatment and 19 completed four weeks.

The active device was a flexible approximately 500-gauss concentric bipolar static magnet.

But again, the placement is particularly interesting.

Researchers palpated multiple areas of the abdomen and selected the two most sensitive abdominal trigger points. Active or sham magnets were then positioned over those locations and worn 24 hours per day.

After four weeks, women completing active treatment had significantly better Pain Disability Index and Clinical Global Impression scores than the placebo group. The authors concluded that static magnetic field therapy significantly improved disability and might reduce pain in chronic pelvic pain.

There was an important problem: participants receiving active magnets were more successful at guessing which treatment they had received, meaning blinding had become compromised.

And chronic pelvic pain is a broader condition than primary dysmenorrhea.

Nevertheless, Brown adds something useful to the menstrual-pain discussion because it provides a third example of static magnetic therapy being applied specifically according to palpated abdominal tenderness rather than simply placing a generic magnetic product somewhere on the body.

Three Studies, Three Very Different Doses

Put the studies side by side and an important pattern emerges.

The devices were different.

The exposure times were dramatically different.

The conditions were not identical.

Yet all three studies share something important: the magnet was deliberately positioned over an anatomically relevant pelvic, painful or tender location.

That is difficult to ignore.

Why These Studies Fit the Field | Dose | Placement Model

One of the problems with decades of arguments about “magnetic therapy” is that magnets are often treated as though they are interchangeable.

They are not.

A flexible 500-gauss concentric magnet, a 2700-gauss directional bipolar device, a 4000-gauss concentric rare-earth magnet and a modern multipolar Q Magnet produce different spatial field environments.

But pooling very different conditions, magnetic geometries, doses and placements creates a second question:

Could the treatment parameters themselves partly explain why some trials succeed and others fail?

A later review of 28 controlled human and animal studies concluded that positive analgesic outcomes appeared to vary according to factors such as magnetic field intensity, treatment duration and pain type, while emphasizing the need for much better parameter-controlled research.

This is exactly the problem addressed by the Q Magnets Field | Dose | Placement (FDP) framework.

Field asks what magnetic geometry is actually being produced.

Dose includes field characteristics, magnet dimensions, tissue depth, exposure duration and cumulative wear time.

Placement asks whether that field is positioned over an anatomically relevant target.

The current Q Magnets education framework explicitly warns against reducing magnetic therapy to a contest over which magnet has the largest gauss number.

The dysmenorrhea research supports that caution.

Eccles produced a positive result using relatively prolonged exposure. Mayrovitz produced one using only 40 minutes but very specific pain-guided placement. Brown combined continuous exposure with palpation-guided trigger-point placement.

How Does This Compare With the Q Magnets Menstrual Pain Protocol?

The current Q Magnets Primary Placement starts with one magnet centrally over the lower pelvic region just above the pubic bone, with another two magnets positioned above it to form a triangular configuration. The exact positions can be adjusted according to the location of the pain. When lower abdominal discomfort is associated with the lower back, the protocol also permits two additional placements over the posterior pelvic/PSIS region.

That means the existing protocol incorporates elements seen independently in the research.

The central lower-pelvic position resembles the basic anatomical approach used by Eccles.

Adjusting placement according to where pain is experienced is consistent with the approach used by Mayrovitz.

And using more than one carefully selected location is conceptually consistent with Brown’s trigger-point approach.

The principal difference is that the Q Magnets protocol uses multiple engineered multipolar devices to cover the pelvic region, rather than relying on one research magnet.

Current options include three QF20-3 devices for a moderate-size field configuration, three QF28-3 devices for broader/deeper coverage, and a larger five-device configuration incorporating QF28-6 and QF28-3 magnets.

These Q Magnets arrangements have not themselves been tested in a randomized dysmenorrhea trial, so it would be inappropriate to imply that the Eccles or Mayrovitz results clinically validate the complete Q Magnets protocol.

What can reasonably be said is that the protocol shares several important treatment principles with the published research: pelvic placement, pain-guided adjustment, sustained static-field exposure and sufficient anatomical coverage.

What About Adjunct Placements?

Primary Placement remains the logical starting point.

However, menstrual pain does not always present as one neat central cramp. Tenderness may occur through the lower abdominal wall, pelvic muscles, lower back or other sites. Some women may also find that the Primary Placement does not provide sufficient comfort on its own.

The current Q Magnets Adjunct Placement framework therefore identifies additional optional sites for menstrual pain, including the acupuncture points SP8, SP6 and CV4, along with trigger-point regions involving the lower rectus abdominis and iliopsoas.

These should not be interpreted as instructions to apply every available magnet simultaneously.

They are alternatives to consider according to the individual pain pattern, areas of tenderness and response to the Primary Placement.

The Brown study is particularly relevant here. It does not validate those individual acupuncture points, nor does it prove the Q Magnets Adjunct Protocol. But it does provide clinical evidence for the broader principle of palpating the abdomen, identifying sensitive trigger points and placing static magnetic fields directly over them.

That makes Adjunct Placement a rational area for further investigation rather than an arbitrary addition to the protocol.

One Important Question the Current Protocol Still Needs to Answer: How Long?

Research gives us three quite different reference points:

Eccles began treatment about two days before the expected period and continued through menstruation.

Mayrovitz obtained a significant result after only 40 minutes.

Brown used continuous exposure for weeks in chronic pelvic pain.

There’s nothing wrong with trialling each or a combination of all three, especially Eccles and Mayrovitz. Whichever method you choose, monitor the skin and response, and use the shortest practical exposure that provides useful comfort. The current Q Magnets Guide already treats duration and cumulative exposure as components of dose.

Future controlled research comparing 40 minutes, several hours and longer continuous wear would be extremely useful.

What About Q Magnets Customer Experiences?

These experiences matter, but they serve a different purpose from randomized research.

A testimonial cannot tell us the probability that a treatment will work, separate treatment effects from placebo responses, or determine what would have happened without the device.

What anecdotes can do is identify real-world patterns worth investigating: where people place the magnets, how quickly they perceive a change, how long they wear them, whether they continue using them, and what practical problems arise.

One Q Magnets customer, for example, reported finding the magnets helpful for menstrual pain and eventually needing them less frequently as her symptoms became easier to manage.

It is the combination of published controlled studies, a biologically testable Field | Dose | Placement model, and accumulated real-world experience that justifies further serious investigation.

So, How Good Is the Evidence Really?

It would be easy to oversell these results.

That would be a mistake.

There are currently only two small randomized studies specifically investigating static magnets for dysmenorrhea. Both reported statistically significant advantages for active magnets, but both should be regarded as pilot evidence rather than definitive confirmation.

The chronic pelvic pain study provides additional supportive evidence, but it studied a different condition and had a compromised blinding problem by the fourth week.

And the wider literature on static magnets for pain is decidedly mixed, but that is not quite the same question as:

Do properly selected static magnetic fields, used with an appropriate dose and accurately placed over the painful pelvic region, help some women with primary dysmenorrhea?

On that much narrower question, the evidence is considerably more interesting.

Both published dysmenorrhea trials answered it in the positive.

That deserves replication.

The Risk-Benefit Question Is Also Different

A treatment does not need to work for everybody to be worth considering.

Its value also depends on its cost, inconvenience and risk.

Q Magnets are passive, reusable devices. They contain no pharmaceutical ingredient and do not expose the user to systemic drug effects. Once purchased, the same devices can be reused rather than requiring a new pharmaceutical purchase with every menstrual cycle.

At current Australian pricing, the existing abdominal/pelvic configurations listed by Q Magnets range from approximately AU$141 for three QF20-3 magnets to AU$237 for three QF28-3 magnets, with a larger five-magnet configuration (Complex Lower Back Pain) listed at AU$525.

That does not make magnets entirely risk-free.

Q Magnets should not be used near magnetically sensitive or programmable implanted devices such as pacemakers, implantable cardioverter-defibrillators, infusion pumps or some neurostimulators. They should not be placed over transdermal medication patches or open wounds, and the safety of Q Magnets during pregnancy has not been established.

Skin should also be monitored when adhesives and prolonged wear are used.

For an appropriately screened user, however, the downside is relatively limited: a reusable non-powered device may provide useful relief, partial relief-or no meaningful benefit.

That is quite a different risk equation from repeatedly taking a systemic medication, especially for someone who would prefer not to do so.

An Important Distinction: Primary Versus Secondary Dysmenorrhea

None of this should encourage women to ignore unexplained or changing pelvic pain.

The dysmenorrhea trials primarily concerned women without identified secondary causes.

Period pain that is unusually severe, becoming progressively worse, occurring outside menstruation, associated with very heavy or unusual bleeding, pain during intercourse, fainting, fever, possible pregnancy or a major change from normal symptoms deserves medical assessment. Conditions such as endometriosis, adenomyosis, fibroids, ovarian disorders and pelvic inflammatory disease can cause secondary dysmenorrhea.

Temporary pain relief-whether it comes from ibuprofen, heat, a magnet or anything else-does not diagnose or remove an underlying disease.

That distinction is particularly important with abdominal and pelvic pain.

Is Static Magnetic Therapy Worth Considering for Period Pain?

For women who are happy with their existing medication and obtain reliable relief, there is no argument here that they should stop.

For women looking for another option, the situation is more interesting.

We have two randomized, blinded clinical studies specifically investigating static magnets for dysmenorrhea.

Both reported significantly better results with active magnets than with their controls.

One used prolonged pelvic exposure beginning before menstruation.

The other used a single 40-minute treatment targeted precisely at the point of greatest pain.

A third randomized study in chronic pelvic pain found benefits after continuous magnets were placed over abdominal trigger points.

None is large enough to provide a final answer.

But taken together, they make it difficult to dismiss static magnetic field therapy for menstrual and pelvic pain as an idea with “no evidence.”

A more accurate conclusion is:

The evidence is not yet definitive, but the combination of a relatively low-risk intervention, reusable technology and positive controlled pilot trials makes further research-and cautious individual consideration-reasonable.

For someone who already has an effective and well-tolerated solution, that may not change anything.

For someone actively searching for a non-pharmaceutical approach to recurring period pain, it may be enough evidence to make a carefully applied trial worth considering.

Learn More

• Abdominal and Menstrual Pain Treatment with Magnetic Therapy
• Abdominal and Menstrual Pain Treatment Protocol
• Adjunct Placement for Acupuncture Points and Trigger Points for Menstrual Pain
• Field | Dose | Placement

References

1. Eccles NK. A randomized, double-blinded, placebo-controlled pilot study to investigate the effectiveness of a static magnet to relieve dysmenorrhea. Journal of Alternative and Complementary Medicine. 2005;11(4):681–687. doi:10.1089/acm.2005.11.681. View on PubMed
2. Mayrovitz H, Milo B, Alexander B, Mastropasqua M, Moparthi Y. Effects of a Concentric Rare-Earth Magnet on Menstrual Cycle Pain: A Parallel Group Randomized Pilot Study. Cureus. 2021;13(1):e12801. doi:10.7759/cureus.12801. View on PubMed
3. Brown CS, Ling FW, Wan JY, Pilla AA. Efficacy of static magnetic field therapy in chronic pelvic pain: a double-blind pilot study. American Journal of Obstetrics and Gynecology. 2002;187(6):1581–1587. doi:10.1067/mob.2002.128026. View on PubMed
4. Pittler MH, Brown EM, Ernst E. Static magnets for reducing pain: systematic review and meta-analysis of randomized trials. CMAJ. 2007;177(7):736–742. doi:10.1503/cmaj.061344. View on PubMed.
5. Fan Y, Ji X, Zhang L, Zhang X. The Analgesic Effects of Static Magnetic Fields. Bioelectromagnetics. 2021;42:115–127. View on PubMed